洛匹那韦/利托那韦与羟氯喹治疗轻至中度新冠病毒病的比较结果：一项回顾性观察研究。
Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study.
作者信息
Lee Jeong Eun, Lee Soon Ok, Heo Jeonghun, Kim Dong Wan, Park Mi Ran, Son Hyunjin, Kim Dongkeun, Kim Kye-Hyung, Lee Shinwon, Lee Sun Hee
机构信息
Department of Internal Medicine, Pusan National University School of Medicine and Medical Research Institute, 220312Pusan National University Hospital, Busan, Korea.
Department of Internal Medicine, 37978Busan Medical Centre, Busan, Korea.
出版信息
Antivir Ther. 2021 Jan-Feb;26(1-2):34-42. doi: 10.1177/13596535211039394. Epub 2021 Sep 2.
BACKGROUND
Lopinavir/ritonavir (LPV/r) and hydroxychloroquine (HCQ) are both being used to treat coronavirus disease 2019 (COVID-19), but their relative effectiveness is unknown. The purpose of this study was to compare the clinical outcomes of patients treated for COVID-19 with LPV/r or HCQ.
METHODS
A retrospective observational study was conducted at 2 hospitals in Busan, South Korea, where approximately 90% of COVID-19 patients were hospitalised during February/March 2020. All patients aged ≥15 years that were hospitalised with mild or moderately severe COVID-19 received LPV/r or HCQ as their initial treatment and were included in the analysis.
RESULTS
Among the 72 patients with mild-to-moderate disease severity on admission, 45 received LPV/r and 27 received HCQ as their initial therapy. A higher proportion of the LPV/r group had pneumonia on admission (LPV/r, 49% vs HCQ, 15%), but there were no other significant differences in the demographic or clinical characteristics between groups. Switching therapy due to clinical failure was significantly more common in the HCQ group than in the LPV/r group (41% [11/27] and 2% [1/45], respectively, .001). Disease progression was also significantly more common in the HCQ group than in the LPV/r group (44% [12/27] and 18% [8/45], respectively, = .030).
CONCLUSION
Based on our study results, HCQ shows no apparent advantage compared to LPV/r for preventing progression to severe disease in patients with COVID-19.
背景
洛匹那韦/利托那韦（LPV/r）和羟氯喹（HCQ）均被用于治疗2019冠状病毒病（COVID-19），但其相对疗效尚不清楚。本研究的目的是比较接受LPV/r或HCQ治疗的COVID-19患者的临床结局。
方法
在韩国釜山的2家医院进行了一项回顾性观察研究，2020年2月/3月期间约90%的COVID-19患者在这两家医院住院。所有年龄≥15岁、因轻度或中度COVID-19住院的患者均接受LPV/r或HCQ作为初始治疗，并纳入分析。
结果
在入院时疾病严重程度为轻度至中度的72例患者中，45例接受LPV/r作为初始治疗，27例接受HCQ作为初始治疗。LPV/r组入院时肺炎的比例更高（LPV/r组为49%，HCQ组为15%），但两组在人口统计学或临床特征方面无其他显著差异。因临床治疗失败而更换治疗方案在HCQ组比LPV/r组更为常见（分别为41%[11/27]和2%[1/45]， = 0.001）。疾病进展在HCQ组也比LPV/r组更为常见（分别为44%[12/27]和18%[8/45]， = 0.030）。
结论
根据我们的研究结果，在预防COVID-19患者进展为重症疾病方面，HCQ与LPV/r相比没有明显优势。
Zotero 插件